ReviewMovement disorders clinical practice2021
De Novo Movement Disorders and COVID-19: Exploring the Interface.
Review in Movement disorders clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Scrub typhus-associated movement and gait disorders: A systematic review with principal component analysis and in silico mechanistic modelling.Tropical medicine & international health : TM & IH · 2025Pooled it
- Theiler's murine encephalomyelitis virus as the infectious agent for a virally induced mouse model of Parkinson's disease.Brain, behavior, & immunity - health · 2026Article
- Pediatric de novo movement disorders and ataxia in the context of SARS-CoV-2.Journal of neurology · 2023Review
- Ataxia Myoclonus Syndrome in Mild Acute COVID-19 Infection.Cerebellum (London, England) · 2023Article
- Parkinsonism Following SARS-CoV-2 Infection Unmasks a Genetic Twist.Movement disorders clinical practice · 2023Article
- Article
- Review
- Neurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder.Viruses · 2023Article
- Worsening of Essential Tremor After SARS-CoV-2 Infection.Cerebellum (London, England) · 2023Article
- Expanding the Spectrum of Diabetic Striatopathy: Insights from a Case of Hyperglycemia-Induced Propriospinal Myoclonus.Tremor and other hyperkinetic movements (New York, N.Y.) · 2023Article
- Parkinsonism with akinetic mutism following osmotic demyelination syndrome in a SARS-CoV-2 infected elderly diabetic woman: A case report.Neurologia · 2022Article
- Viruses, parkinsonism and Parkinson's disease: the past, present and future.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Eye Movement Alterations in Post-COVID-19 Condition: A Proof-of-Concept Study.Sensors (Basel, Switzerland) · 2022Article
- Viral Parkinsonism: An underdiagnosed neurological complication of Dengue virus infection.PLoS neglected tropical diseases · 2022Article
- Comment on "Chorea as a Presentation of SARS-CoV-2 Encephalitis: A Clinical Case Report".Journal of movement disorders · 2022Article
- The Rise of Functional Tic-Like Behaviors: What Do the COVID-19 Pandemic and Social Media Have to Do With It? A Narrative Review.Frontiers in pediatrics · 2022Review
- Acute Hemichorea-Hemiballismus Following COVID-19 (AZD1222) Vaccination.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.Journal of neuroimmunology · 2021Article
- De Novo Movement Disorders Associated with COVID-19- A Systematic Review of Individual Patients.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being widely documented. However, movement disorders in the setting of 2019 coronavirus infectious disease (COVID-19) have been a strikingly less discussed topic. Objectives: To summarize available pieces of evidence documenting de novo movement disorders in COVID-19. Methods: We used the existing PRISMA consensus statement. Data were collected from PubMed, EMBASE, Web of Science, and Scopus databases up to the 29th January, 2021, using pre-specified searching strategies. Results: Twenty-two articles were selected for the qualitative synthesis. Among these, a total of 52 patients with de novo movement disorders were reported. Most of these had myoclonus, ataxia, tremor or a combination of these, while three had parkinsonism and one a functional disorder. In general, they were managed successfully by intravenous immunoglobulin or steroids. Some cases, primarily with myoclonus, could be ascribed to medication exposures, metabolic disturbances or severe hypoxia, meanwhile others to a post-or para-infectious immune-mediated mechanism. SARS-CoV-2 could also invade the central nervous system, through vascular or retrograde axonal pathways, and cause movement disorders by two primary mechanisms. Firstly, through the downregulation of angiotensin-converting enzyme 2 receptors, resulting in the imbalance of dopamine and norepinephrine; and secondly, the virus could cause cellular vacuolation, demyelination and gliosis, leading to encephalitis and associated movement disorders. Conclusion: De novo movement disorders are scantly reported in COVID-19. The links between SARS-CoV-2 and movement disorders are not yet established. However, we should closely monitor COVID-19 survivors for the possibility of post-COVID movement disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.